Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going?
In this webinar, Henry A. Nasrallah, MD and Rifaat El-Mallakh, MD, review foundational concepts related to the cytochrome p-450 system with an emphasis on current genetic testing capabilities, issues related to individual variability, and impact on treatment, tolerability, and outcomes. Speakers also explore the differences between biomarkers and genetic testing, and ends with a discussion of potential trends in the future for personalized medicine.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.